
==== Front
NPJ Aging
NPJ Aging
NPJ Aging
2731-6068
Nature Publishing Group UK London

168
10.1038/s41514-024-00168-y
Review Article
The paradox of senescent-marker positive cancer cells: challenges and opportunities
O’Sullivan Emily A.
http://orcid.org/0000-0001-8430-3356
Wallis Ryan
http://orcid.org/0000-0003-2165-898X
Mossa Federica
Bishop Cleo L. c.l.bishop@qmul.ac.uk

https://ror.org/026zzn846 grid.4868.2 0000 0001 2171 1133 Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
14 9 2024
14 9 2024
12 2024
10 1 4129 2 2024
15 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Senescence is an anti-tumour mechanism and hallmark of cancer. Loss or mutation of key senescence effectors, such as p16INK4A, are frequently observed in cancer. Intriguingly, some human tumours are both proliferative and senescent-marker positive (Sen-Mark+). Here, we explore this paradox, focusing on the prognostic consequences and the current challenges in classifying these cells. We discuss future strategies for Sen-Mark+ cell detection together with emerging opportunities to exploit senescence for cancer.

Subject terms

Senescence
Cancer
https://doi.org/10.13039/501100009187 RCUK | MRC | Medical Research Foundation DERB1E1R O’Sullivan Emily A. https://doi.org/10.13039/501100007705 University of Western Ontario | Robarts Research Institute (Robarts Research) Barts Charity Grant Ref MGU0537https://doi.org/10.13039/501100000268 RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/T008709/1 Mossa Federica issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Senescence is a homeostatic cellular programme that is activated in response to a plethora of stressors. In response, Cyclin Dependent Kinase inhibitors (CDKi), such as p16INK4a (p16; encoded by the CDKN2A locus) and/or p21WAF-1/CAP1 (p21), are upregulated to initiate and maintain a stable cell cycle arrest. A further defining feature of senescence is an altered, hypersecretory phenotype, the composition of which is both trigger-dependent and temporally dynamic. The senescence-associated secretory phenotype (SASP) can contain a myriad of components, including proteins (interleukins, cytokines, chemokines, growth factors, proteases etc.), small extracellular vesicles, bioactive lipids and non-coding nucleic acids (e.g. miRNAs, cytoplasmic chromatin fragments) (reviewed in ref. 1). Emerging evidence suggests that the physiological setting governs whether the paracrine effect of the SASP has a beneficial or detrimental consequences for the local tissue microenvironment (TME).

Oncogene-induced senescence (OIS) is an established form of premature senescence that can be triggered following oncogene activation or tumour suppressor inactivation. Once established, OIS acts to prevent the replication of damaged cells at risk of malignant transformation, and is, therefore, considered a key tumour suppressor mechanism. Although not fully elaborated mechanistically, senescence escape refers to the re-acquisition of proliferative potential following senescence induction (reviewed in ref. 2). Subsequent, successive rounds of error-prone replication in these pre-cancerous cells can lead to the accumulation of more DNA damage and increased genomic instability, thereby allowing further pro-tumourigenic mutations to take place3. Thus, cancer evolution can result in proliferative tumour cells harbouring mutations in key senescence effector molecules. However, contrarily, some tumours are able to proliferate whilst also expressing high levels of key senescence effector proteins. These enigmatic ‘Senescent Marker Positive’ (Sen-Mark+) cancer cells have, to date, received comparatively little attention.

In this review, we chart the discovery of OIS and summarise the role of senescence as an intrinsic tumour suppressor mechanism. We outline examples where non-malignant senescent cells contribute to the tumour microenvironment (TME), specifically, the emerging evidence that such senescent cells can be detected within the stroma. Then, we describe the evidence for Sen-Mark+ cancer cells, with a particular focus on the key senescence effectors p16 and p21. We describe the current understanding of the different prognostic implications for Sen-Mark+ cancers and consider the challenges when attempting to classifying Sen-Mark+ cancer cells. Finally, we set out therapeutic opportunities to target Sen-Mark+ cancers and discuss the important considerations of such treatment regimes. The definitions of key senescence-related processes are outlined in Fig. 1.Fig. 1 The definitions of key senescence-related processes.

This figure provides definitions with diagrammatic examples of key senescence-related processes used within this review.

p16 and p21 as key senescence effectors

The CDKi p16 and p21 play important roles as key senescence effectors. The canonical function of the tumour suppressor p16 occurs in the nucleus, during the transition of G1 to S phase of the cell cycle. Here, binding of p16 to CDK4/6 prevents the hyperphosphorylation of retinoblastoma protein (RB, pRb), maintaining the sequestration of E2F family of transcription factors, preventing S phase entry and cell cycle progression (see Fig. 2). Whilst p16 functions exclusively in the G1 to S transition, p21 can inhibit CDK4/6-cyclin D, CDK1-cyclin B1 and CDK1/2-cyclin A complexes, inhibiting the cell cycle at G1 and G2, respectively.Fig. 2 The p16/RB and p53/p21 signalling pathways in response to cell stress.

Senescence inducing stimuli can result in the depression of the CDKN2A locus, allowing for the expression of CDKI p16. ANRIL, antisense lncRNA in INK4 locus, recruits PcG proteins to the CDKN2a locus. Here, EZH2, the catalytic subunit of PRC2, methylates H3K27, recruiting PRC1 to the locus and represses gene expression. The SWI/SNF chromatin remodelling complex, replaces the Bmi1 component of PRC1, exchanging histone methylation with acetylation. Catalytic subunits BRG1 and hSnf5 are essential for relaxing the histone conformation, allowing for transcription. Additionally, a range of senescence-inducing stimuli are capable of activating the DNA damage response (DDR), resulting in the stabilisation of p53 and subsequent transcriptional activation of the cyclin-dependent kinase inhibitor (CDKi) p21. Both p21 and p16 are capable of inhibiting cell cycle progression by targeting the cyclin dependent kinase/ cyclin complexes active in G1. ATM ataxia-telangiectasia mutated, ATR ataxia-telangiectasia and Rad3 related, CDK cyclin-dependent kinase, CHK1 checkpoint kinase 1, CHK2 checkpoint kinase 2, MDM2 mouse double minute 2 homolog, RB retinoblastoma protein.

Oncogene-induced senescence (OIS) as a tumour suppressor mechanism

The first evidence for OIS was published in 1997 in IMR90 fibroblasts, where the expression of an oncogenic Ras allele resulted in permanent G1 arrest with features of senescence4. Subsequently, a series of landmark studies demonstrated that OIS occurs in vivo, including in the hematopoietic compartment (T-cell)5, naevi6–8, pituitary gland9, lung tissue10,11, prostate epithelium12–14 and kidneys15.

Further evidence for the tumour suppressive role of senescence comes from the observation that senescent cancer cells are mainly detected in pre-malignant stages of cancer development (reviewed in ref. 16). Additionally, mutations within senescence pathways are frequently observed in cancer, enabling neoplastic cells to proliferate, and perpetuate genetic instability towards malignant transformation. For example, early studies in prostate cancer driven by Pten loss in mice demonstrated an upregulation of p19ARF followed by p53 and p21, resulting in senescence induction12. Subsequent loss of Trp53 allowed for the resumption of proliferative capacity and complete transformation of the pre-malignant cells. Similarly, high expression of oncogenic HrasG12V in a mouse model of mammary tumorigenesis resulted in senescence induction in a p16-dependent manner17. In humans, melanocytic naevi6, and adenomas of both the lung10 and colon18, demonstrate high expression of the senescence marker p16 in the pre-malignant but not the malignant counterpart, reinforcing the early protective role of senescence in cancer.

Senescence escape

Senescence escape is defined as the re-acquisition of proliferative potential following senescence induction (reviewed in ref. 2). This process is well documented in normal epithelial cells, occurring via a two-step process (reviewed in ref. 19). A first in vitro arrest, often referred to as “stasis” or “M0”, occurs via elevated p16 signalling. However, through hypermethylation of the p16 promoter, ~1 in 104 cells can escape this process and re-enter the cell cycle, before entering a stable p21-dependent senescence programme following replicative exhaustion20,21. Of direct relevance, carcinomas are cancers which are epithelial in origin and account for up to 90% of all human cancers. Thus, senescence escape has been proposed as one potential route to carcinoma development.

In support of this model, several reports have demonstrated that senescence escape can occur through the genetic mutation of key senescence genes, for example via the loss of p16-pRb22 or p53-p21 signalling12,23, or following the reactivation of telomerase activity24. Furthermore, the most frequently mutated tumour suppressors in human cancers are the INK4/ARF locus or p53 (reviewed in refs. 25,26). The INK4/ARF locus comprises p15INK4b, p16 and p14ARF (Alternative Reading Frame, ARF; p14ARF in humans, p19ARF in mice), transcribed in alternate reading frames of the CDKN2A gene, and is subject to extensive transcriptional regulation (reviewed in ref. 27). Germline mutations in p16 are seen in familial melanoma, preventing the binding of p16 to CDK4 and allowing for uncontrolled proliferation (reviewed in ref. 28). Although the INK/ARF locus encodes two tumour suppressors, alterations to p16 expression alone are far more prevalent, with impairment of ARF activity only occurring in conjunction with loss of p16 function26. Generally, p16 expression is lost in human cancers either through homozygous deletion or promoter hypermethylation (reviewed in ref. 29). The loss of p53 function confers a substantial survival advantage to pre-cancerous cells, in part due to the consequential lack of p21 expression, as p53 directly activates p21 transcription25 (see Fig. 2). For example, Li-Fraumeni syndrome patients are predisposed to early onset, widespread tumour development as a result of germline p53 mutation, emphasising the protective role of p5330. More commonly, p53 is inactivated directly through mutations in the p53 gene in over half of human cancers.

In summary, these observations suggest that perturbation of senescence programmes via senescence escape represents a route to cancer development. It is important to note that other possible routes exist. For example, tumorigenesis could potentially occur without a cell formally entering a stable cell cycle arrest, a process termed senescence bypass. Differentiating between senescence escape and senescence bypass is fundamentally challenging when considering cancer evolution in vivo.

Senescence and cancer

Non-malignant senescent cells in the TME

It is well established that cancer cells have complex, dynamic, and bidirectional interactions with neighbouring stromal cells. There is now growing evidence that non-malignant senescent cells, including fibroblasts, endothelial cells and immune cells, present within the TME can contribute to this crosstalk. The question as to how and when these cells enter senescence is one of great interest, with emerging evidence suggesting that senescent stromal cells can be detected prior to tumour development. The role of senescent stromal cells is likely underpinned by their precise secretory profile, in a TME context-dependent manner. For example, Ruhland and colleagues established an inducible p27Kip1 model of in vivo senescence specifically in cells of mesenchymal origin. In this model, senescent mouse fibroblasts displayed elevated secretion of the canonical SASP factor, interleukin-6 (IL-6), and co-injection of senescent fibroblasts led to an increase in Ras-induced tumour growth, suggesting that non-malignant senescent stromal cells can drive tumour development31. More recently, Prieto et al.32 and Haston et al.33 have used a KRas-driven mouse models of lung cancer to uncover a pro-tumorigenic role for senescent macrophages. These publications also find that macrophages with senescent features are detected in normal, aged mice and pre-malignant human lesions, raising the spectre that their presence may prime neighbouring epithelial cells for neoplastic transformation. Further, the demonstration that genetic or pharmacological removal of senescent macrophages decreased tumour burden and increased survival illuminates routes for future therapeutic innovation. Taken together, these findings illustrate that non-malignant stromal cells add a further dimension to tumour biology.

Senescent-marker positive (Sen-Mark+) cancer cells

As detailed above, the loss of key senescence effectors has classically been viewed as an essential step in tumour development. However, of direct relevance to this review, a subset of treatment naïve human tumours express canonical senescent effector proteins whilst simultaneously, but paradoxically, maintaining a high proliferative index. Here, we focus on p16+ and p21+ cancer cells. These underexplored ‘senescent-marker positive’ (Sen-Mark+) cancer cells create challenges, including accurate classification of senescence within the tumour, and opportunities, such as the potential for diagnostic and prognostic biomarkers. They also raise the question as to whether Sen-Mark+ cancer cells could drive therapy resistance, and if their unique expression profiles can be exploited for the treatment of these subtypes of cancer.

p16 overexpression in cancer

Although p16 function is lost in over half of all human cancers34, an interesting paradigm is emerging where p16 is detected and even overexpressed in malignancy. For example, in HPV-related cancers, p16 is often overexpressed as a result of the viral E7 oncoprotein preventing SUZ12 binding, thereby inactivating RB and releasing p16 from a negative feedback loop35. In this context, p16 expression is associated with better overall survival36. Although the viral E7 protein inactivates RB, mutations in Rb1 alone are only commonly seen as a driver in retinoblastoma and small cell lung cancer, and occur as a late event in other malignancies (reviewed in ref. 37). This raises an interesting conundrum. If p16 function was exclusive to the RB pathway, it would be logical that inactivation of this pathway would occur through the targeting of p16 or RB. Furthermore, although the RB1 pocket proteins are structurally similar to RB, mutations are not seen in p107 (RBL1) or p130 (RBL2)37. Therefore, cells that develop into cancer have preferentially lost p16 function and not the p16-RB pathway alone.

The selective pressure for cancer cells to lose p16 function, and not just the p16-RB pathway, highlights the potential alternative functions p16 may have, and what other mechanisms may exist to inactivate them. For example, in a lung epithelial model the expression of p16 is protective against DNA damage induced by bleomycin treatment, even when Rb1 is deficient38. Therefore, it is important for future studies to consider protective functions of p16 beyond RB and potentially beyond the pocket protein family.

Surprisingly, the overexpression of the CDKi p16 has been reported to correlate with disease progression and poorer patient outcome in some cancer subtypes. Reconsideration of the original staining criteria established by Geradts et al. in 199539, has led to the inclusion of cytoplasmic p16 in defining a positive signature. This has been essential to exploring alternative functions of p16 in cancer. In a study of gastrointestinal stromal tumours (GISTs), Haller et al. utilised two monoclonal anti-p16 antibodies for both Western blot and immunohistochemistry analysis, to gain confidence in the cytoplasmic localisation of p1640. Patients with high cytoplasmic p16 staining had shorter overall survival time, independent of anatomic tumour site. Interestingly, the cytoplasmic localisation of p16 was found only in cancerous cells, whereas nuclear positivity was detected in non-neoplastic cells. Given the canonical CDKi function of p16 occurs in the nucleus, the prevalence of cytoplasmic staining in a variety of cancers raises questions regarding alternative non-canonical roles for p16, or how cancer cells may adapt alternative methods to enable progression through the cell cycle despite retaining a p16-positive status.

The cytoplasmic localisation of p16 is not restricted to GISTs. In ovarian cancer without HPV infection, p16 overexpression within the nucleus and cytoplasm is present in invasive serous papillary carcinoma, without the loss of RB41. Intriguingly, Todd and colleagues demonstrated that ectopic overexpression of p16 in p16-positive ovarian cancer cell lines did not result in a cessation of the cell cycle, despite co-expressing RB, suggesting that unidentified downstream pathway defects could be present42. Furthermore, Zhao et al. demonstrated cytoplasmic p16 staining in adenomas and carcinomas arising from colorectal epithelial cells43. A study of 194 patients with colorectal adenocarcinoma also demonstrated p16 expression in 80% of tumours, with overexpression in 48%. Similarly to GISTs, cytoplasmic p16 was associated with a more aggressive disease and reduced survival time44. In squamous cell carcinoma, p16 expression did not affect proliferation rates, with p16-expressing keratinocytes present at the invasive front45. Interestingly, invasive squamous cell carcinoma predominantly exhibited only cytoplasmic p16. Similarly, oral squamous cell carcinoma demonstrated increased expression of p16 and p53 as the disease progressed from mild dysplasia to invasive carcinoma using immunohistochemistry46.

Milde-Langosch and colleagues explored the expression level of p16 and RB in 60 mammary carcinomas and four cell lines in comparison to normal mammary tissue. Surprisingly, both nuclear and cytoplasmic p16 was detected in most carcinomas, with a high level of expression in 9 cases47. High p16 expression was not associated with a change in RB expression but associated with a high proliferative index measured by Ki67 expression, more aggressive tumours, and poorer patient prognosis. The high proliferation rate of these tumours despite expressing the potent CDKi p16 is perplexing and challenges our current understanding on the roles and regulation of p16. Furthermore, this work supports previous observations that subcellular distribution of p16 could represent an underappreciated nuance to tumour classification48.

Basal-like breast cancer (BLBC) is a highly aggressive and invasive subtype of breast cancer, that has been reported to overexpress both nuclear and cytoplasmic p1649,50. As BLBC is commonly triple negative, it lacks any targeted therapies. Recently, the overexpression of both nuclear and cytoplasmic p16 has been suggested as a biomarker of poor prognosis in BLBC50. Therefore, a marker usually used to denote a senescent state, here denotes the polar opposite: a highly proliferative and aggressive cancer cell.

The cytoplasmic localisation of p16 could have unexplored therapeutic benefits. Shen and colleagues explored the cytoplasmic localisation of p16 in gastric and colonic adenocarcinomas, demonstrating a cytoplasmic interaction with anion exchanger 1 (AE1)51. Subsequent knockdown of AE1 using siRNA, resulted in both the translocation of p16 into the nucleus and a cessation of proliferation. This work highlights that non-canonical mechanisms of p16 regulation exist that may be exploited by cancer cells to prevent the induction of senescence.

Taken together, these examples illuminate the underexplored relationship between p16 overexpression and cancer. By understanding how these cancer subtypes have managed to escape, or bypass, senescence induction without the loss of p16, not only would the field gain valuable insight into unknown regulation mechanisms and functions of p16, but also there is the opportunity to exploit this overexpression as a new therapeutic strategy.

p21 overexpression in cancer

Although p53 is frequently mutated in cancer, p21 mutations are rare. Outside of the nucleus, alternative roles of p21 in the cytoplasm have also been reported, such as inhibiting apoptosis by forming a complex with the apoptosis signal-regulating kinase 1 (ASK1) (reviewed in ref. 52). Furthermore, p21 can be activated in p53-independent methods, raising interesting questions regarding non-canonical functions within a p53-mutated cell.

Similarly to p16, both loss and overexpression of p21 have been reported with conflicting effects depending on the cancer type. In gastric cancers, p21 is detected in both the nucleus and cytoplasm, with cytoplasmic p21 being associated with metastasis and reduced overall survival53. In HER2-positive breast cancer, a phosphorylated form of p21 is overexpressed, with high cytoplasmic localisation being predictive of poor prognosis54. It was therefore suggested that phospho-p21 could be used as a predictor for patient survival in HER2-positive breast cancer.

Using an array of human tumours, Galanos et al. demonstrated an association of the CDKi p21 with the proliferative marker Ki6755. Furthermore, Galanos explored ability of osteosarcoma cells to escape senescence, showing that p21-expressing, p53-deficient cells regained proliferative capacity after 20 days. Cells that escaped had greater genetic instability and a more invasive phenotype, despite expressing p21. This was later attributed to a switch from RAD-51 DNA repair to the more error-prone RAD52-dependent break-induced replication56. By understanding how these cells have escaped senescence induction, a dependency on RAD52 has been exposed which could be exploited as a synthetic lethality therapeutic.

Interestingly, p21 overexpression in cancer cells can also lead to chemotherapeutic resistance. Alpelisib (BYL719) is a PI3Kα inhibitor, therapeutically used for PIK3CA-mutant, ER+ metastatic breast cancer57. Using integrative modelling of the T47D ER+ breast cancer cell line, Yip and colleagues explored the emergence of Alpelisib-resistant pools58. Here, resistant cells demonstrated nuclear p21 expression but low expression of the senescent marker, senescence-associated β-galactosidase (SA-β-Gal). In this context, expression of p21 in resistant pools allowed for the repair of DNA damage and subsequent bypass of therapy-induced senescence (TIS).

Taken together, the counterintuitive finding that p16 or p21 positive cancers occur and that this signature can be predictive of poor prognosis raises the challenging question as to how these cancers arose, and if this involved escape or bypass from an original senescence programme. These observations also suggest that alternative mechanisms to inactivate senescence may exist beyond genetic mutations, deletions, or promoter methylation of key effectors of this programme59. However, to explore the role of senescent-positive cancer cells in tumorigenesis and the potential to therapeutically target these cells, there are several challenges that need to be addressed. An important step will be the establishment of a reliable method to accurately define senescence-positive cancer cells. The obstacles in developing such methods and the therapeutic avenues for the restoration of tumour suppressor function through pro-senescence therapy are explored below.

Exploiting senescence as a therapy in cancer

As detailed above, senescence is a bone fide tumour suppressor mechanism. Thus, engaging this cellular programme in malignant cells is a targeted therapeutic concept which is gathering momentum. This is in part because of a growing number of strategies to induce senescence in cancer cells in vivo combined with the potential that senescent cancer cells could be removed either pharmacologically and/or via immunotherapy-based approaches.

Therapy-induced senescence

Conventional first-line cancer treatments, such as chemotherapy and radiotherapy, elicit persistent DNA damage with the aim of cancer cell eradication. However, it is now appreciated that these treatments can induce “off-target” senescence at sub-lethal doses, a phenomenon named TIS. Whilst TIS could, in theory, represent an alternative beneficial outcome for anticancer therapies, lingering senescent cancer cells are associated with immune evasion, polyploidy, senescence escape and tumour relapse60. Indeed, persisting chemotherapy-induced senescent tumour cells have been shown to evade immunosurveillance though the upregulation of immunosuppressive checkpoint proteins including PD-L1, CD80 and PD-L261,62. In this context, the combination of chemotherapy with checkpoint inhibitors could be explored to circumvent the vulnerabilities arising from TIS. Moreover, TIS results in the increased induction of polyploidy due to DNA replication without cell division in several types of cancer63–66. For example, Puig and colleagues showed that following treatment with cisplatin, PROb colon cancer cells initially stopped mitotic activity and expressed markers of senescence (including SA-β-Gal and increased expression of p16 and p21), but maintained DNA synthesis. These mono- or multi-nucleated cells eventually regained proliferative capacity and resisted further chemotherapeutic treatment, accounting for tumour relapse after initial efficient chemotherapy63. Given these and other findings, there is a growing focus on understanding the role of senescence escape in relation to TIS, to provide better treatment options and avoid relapse.

Pro-senescence therapies

Traditional chemotherapeutics aim to target cancerous cells through the induction of DNA damage, therefore targeting cells that are rapidly dividing. Although this can be effective, the non-specific nature of chemotherapies means the side effects are severe, applying additional strain to the patients and their quality of life67. More recently, research has focused on developing targeted therapies which often exploit dependencies or characteristics that are specific to cancerous cells, thus not damaging normal cells.

Given the role of senescence as a barrier to cancer development, the re-establishment of a senescence programme in cancer cells, often called pro-senescence therapy, has emerged as an attractive therapeutic strategy (reviewed in ref. 68). Pro-senescence therapies aim to reactivate or mimic the effectors of senescence, such as p16 or p53, allowing for the intrinsic tumour mechanism to be engaged. Conceptually, this differs from TIS, where senescence induction is an “off-target effect” of a cytotoxic chemotherapeutic agent (reviewed in ref. 69).

To date, several groups have attempted to identify compounds with the capacity to directly induce senescence in cancer cells. By screening a synthetic compound library, a group of compounds called Nutlins were identified to prevent the inhibitory binding of MDM2 to wild type p53, leading to elevated levels of p53 and p21 and subsequent cell cycle arrest70. Although effective, Nutlins depend on the expression of wild type p53, which we know to be heavily mutated in human malignancies. Therefore, although these compounds are able to function in a pro-senescence capacity, this is limited to cancer subtypes with wild type p53 expression. An alternate drug screen conducted in an osteosarcoma cell line with a mutant p53 protein, identified a compound named PRIMA-1 that was able to restore DNA binding capability to mutant p53, resulting in apoptosis and tumour suppression when tested in vivo71. PRIMA-1 therefore has an advantage over Nutlins and could be used to induce senescence in cancers where p53 is mutated.

Impairment of the G1/S restriction point through the loss of p16 function imparts a profound proliferative advantage to cancer cells. To circumvent this, pyridopyrimidines that had previously been shown to inhibit CDKs, were screened to find a compound capable of inducing a G1 arrest through the inhibition of CDK4-cyclin D activity72. The discovered cytostatic compound, PD-0332991 or Palbociclib, demonstrated antitumour efficacy when tested against tumour xenograft models. In 2015, Palbociclib was licenced for treatment of oestrogen positive (ER+), HER2-negative breast cancer in combination with the aromatase inhibitor letrozole, to lower oestrogen levels73. Two further CDK4/6 inhibitors have subsequently been discovered, Abemaciclib and Ribociclib74. Although CDK4/6 inhibitors show benefit in a subset of cancers, resistance to therapy can arise through spontaneous mutations in RB175 or the overexpression of CDK676. Interestingly, high p16 expression in ER+ breast cancer patient-derived xenografts resulted in resistance to Ribociclib77. Of these resistant tumours, 17% had normal levels of RB suggesting that high levels of p16 alone are predictive of resistance. It has also been demonstrated that prolonged treatment with CDK4/6 inhibitors can result in senescence in stromal fibroblasts, resulting in pro-tumorigenic SASP secretion78.

Senolytics

Senolytics are a class of molecules that selectively eliminate senescent cells (reviewed in refs. 79,80). These were developed following seminal work demonstrating that accumulation of senescent cells contributes to a range of age-related pathologies and that selective senescent cell clearance alleviates these effects81. Early senolytics included combination treatment with Dasatanib and Quercertin, which have been successfully used to limit age-related functional decline in mice82,83. However, senolytic activity has proven to vary widely in efficacy between different senescent contexts and the list of senolytics continues to grow, including cardiac glycosides, and perhaps the most widely used BCL-2 inhibitors such as Navitoclax84–86.

The relevance to cancer comes from an innovative approach from Wang et al., who propose a “one-two punch” method to cancer cell clearance87. The first punch involves the pharmacological activation of senescence using pro-senescence approaches. This is then followed by a second senolytic punch, facilitating the selective clearance of the now senescent cancer cell. This approach generates the benefit of senescence induction in the context of cancer, whilst avoiding the potential deleterious effects of senescent cell accumulation67,88. However, it relies on the availability of both a reliable means of senescence induction in the required cancer model, as well as a paired effective senolytic. As a therapeutic strategy, it may be preferable to find a senescent cancer cell selective senolytic, due to the homeostatic role of senescent cells in other tissues including roles in wound healing and development89. The second punch could also be beneficial following routine chemotherapeutic treatment to circumvent the challenges that TIS poses both within cancer cells and the stroma.

Furthermore, concerns have been raised about tissue loss associated with senescence clearance, particularly in aged individuals where senescent cells accumulate and might contribute to the tissue structural integrity. In this context, the use of senomorphic compounds to inhibit or modulate the pro-tumorigenic SASP might be more appropriate.

Immunotherapy based approaches

The interaction between senescent cells and the immune system is complex, primarily due to the varied SASP profile that emerges between different senescence triggers and cell types. The SASP has been implicated a means of senescent cell clearance, with factors such as IL-8 facilitating the recruitment of innate immune cells including NK cells, macrophages, and neutrophils90,91. In the context of cancer, in a KRAS-mutant lung cancer patient-derived xenograft model, coupling of a mitogen-activated protein kinase inhibitor and a pro-senescence CDK4/6 inhibitor, impaired tumour growth to a greater extent than either drug alone92. A mouse model of lung cancer (KrasG12D/+;Trp53−/−) was used to further demonstrate that combination therapy resulted in enhanced immune clearance of the tumour by NK cells. This immune mediated clearance was reduced when the SASP was diminished through NF-kB knockdown. Therefore, the induction of senescence in a cancerous cell has the potential to alter its secretome, resulting in pro-inflammatory factors being secreted and provides an opportunity for immune-mediated clearance. However, the SASP has also been demonstrated to have an immunosuppressive effect31. Understanding the balance between positive and detrimental roles of the SASP will be essential to the design of senescence based therapeutic intervention.

Adaptive immunity

More recently, characterisation of the senescence “surface-ome” has provided insight into the engagement of an adaptive immune response by senescent cancer cells, through identification of an upregulation of the major histocompatibility complex I (MHC-I). This, in combination with the development of a pro-immunogenic immunopeptidome, makes senescent cancer cells sensitive to cytotoxic clearance via CD8 + T cells. Excitingly, this senescence-driven adaptive immunity also facilitated the clearance of non-induced cancer cells in vivo, when engaged through either a prophylactic or treatment based “senescent cell vaccination”93,94. This opens new avenues for therapeutic development, with implications in both cancer immunotherapy and the instigation of a “senolytic” adaptive immune response.

Challenges for senescence classification in cancer

Prima facie senescence and cancer represent diametrically opposed cell fates that might intuitively be anticipated to be distinguishable with relative ease. However, as detailed above, non-malignant senescent cells can be detected within the TME, Sen-Mark+ cancer cells define a subset of treatment naïve tumours, and emerging therapeutic strategies aim to establish senescence in cancer cells. Taken together, classification of these three categories of cell types can be technically challenging, due to the context dependent presence or absence of canonical senescence hallmarks (Fig. 3). This is exacerbated by broader issues facing the senescence field; that there remains no universal marker of senescence and that variability exists between contexts of different cell types, inducers and tissues (reviewed in ref. 95). Consequently, both individually and in combination, senescence markers that are considered canonical may be misleading or lack utility when used as a means of senescence identification in cancer.Fig. 3 Challenges for senescence classification in cancer.

Hallmarks of a classical senescence response typically involve cessation of the cell cycle, increased expression of cyclin-dependent kinase inhibitors (e.g. p16, p21), increased markers of DNA damage, increased lysosomal activity (e.g. SA-β-Gal) and secretion of a senescence-associated secretory phenotype (SASP). However, these markers are frequently present in SenMark+ cancer cells, limiting their utility as identifiers of senescence, which thus represents a significant technical challenge.

Tumour suppressors

The critical role of tumour suppressors (p53-p21 and p16) in restraining the development of malignancy means that the failure of these pathways is generally a prerequisite of cancer development96. This can occur through mutation of the tumour suppressors themselves, either leading to total knockout or heterozygous mutations that lead to dominant negative functional repression (e.g. p53)25. Alternatively, the pathway may be disrupted downstream of the tumour suppressor, as has frequently been observed in the reciprocal RB-null state of many p16 positive cancers (reviewed in ref. 97). Consequently, these cancer cells are positive for these widely relied upon senescence markers but avoid their tumour suppressive role98. This makes identifying senescence in Sen-Mark+ cancers particularly challenging, an issue with which the field is still grappling.

Proliferation

The loss of cellular proliferation is an intrinsic feature of senescence that provides an obvious distinction from the uncontrolled cell division associated with cancer99. By definition, if a cell is proliferating, it cannot be senescent. In the context of Sen-Mark+ cancer cells (e.g. p16+ or p21+ cells), these cells will be positive for both these canonical CDKi and proliferation. When considering pro-senescence therapies, proliferation rates are generally assessed across a population of cells within an in vitro condition, and the potential for mixed populations within cell culture conditions makes the use of proliferation problematic as a classifier of senescence alone. This is particularly the case with senescent cancer cells, as the high proliferative rate of non-senescent cancer cells can quickly overtake the population100. Therefore, experimental conditions must be carefully optimised to determine an appropriate endpoint where senescence can be detected101.

This disparity between proliferation rates is a particular issue in the context of high-throughput screening, where identifying senescence conditions within negative selection screens (e.g. via loss of proliferation) is hindered by low signal-to-noise ratios102. Utilisation of final cell numbers to determine proliferation loss is also limited due to similar readouts occurring through toxicity and cell death. This can be mitigated to a degree through the use of proliferation markers, such as EdU incorporation or Ki67 positivity, to demonstrate the final population contains arrested cells, as opposed to a recovering population that has avoided toxicity103. Therefore, whilst it is crucial to observe a loss of proliferation when attempting to classify senescent cancer cells, this is insufficient if in isolation101. Generally, it is accepted best practice to couple loss of proliferation with additional senescence hallmarks to construct a panel of established markers95. However, as detailed below, conforming to this blueprint is challenging in many cancer contexts.

Other markers

A wide range of senescence markers have been proposed, which usually require tailoring to the specific context of the model system under investigation. However, as in all fields, some have proven more popular than others, and are seen as the “go to” for senescence classification95. Increased SA-β-Gal activity is one of the longest-standing markers of senescence and represents a useful assay which exploits the enhanced lysosomal content generally associated with senescent cells104. However, the SA-β-gal marker has proved to be limited, with comparable activity observed in quiescent cells105. Furthermore, cancer cells often also have increased lysosomal levels and frequently appear “positive” for SA-β-gal106. This can be the case whether the cancer cell is Sen-Mark+ or not, and as an assay has the potential to generate false positives. The assay itself is also notorious for requiring careful optimisation and is sensitive to considerations of cell confluency105,107. Therefore, as a means of distinguishing between proliferating and senescent cancer cells, it must be employed with caution.

Another widely utilised marker is the assessment of features of DNA damage108. This is most relevant in contexts where senescence induction occurs through relevant stimuli, such as exposure to ionising radiation or cytotoxic compounds. However, many cancers are also associated with the DNA damage response pathway, so standard markers, such as γH2AX staining, in isolation are insufficient to classify a cancer cell as senescent109.

The acquisition of the SASP is an extremely well-established hallmark of senescence110. However, the SASP has been shown to be highly context-dependent, varying across triggers and cell types, as well as dynamically developing across the course of senescence induction111. In this, it reflects the challenges of senescence hallmarks in general. Recently, it was demonstrated that the principal determinant of SASP factors associated with senescent cancer cells is the parental cell itself112. Therefore, it would be a challenge to rely upon any individual or combination of secreted factors to confidently classify cancer cells as senescent113. It is important to emphasise that often senescence markers have been assessed in the context of non-malignant cells (mainly fibroblasts). Therefore, it is perhaps unsurprising that markers of senescent epithelial cancer cells themselves are less developed. However, recent efforts within the field have begun to redress that balance.

Overcoming the challenge with machine learning

A major new tool in the repertoire of researchers aiming to identify senescent cancer cells is the increasing accessibility of machine learning (ML) algorithms114,115 (Fig. 4). These have recently been employed to demonstrate that senescent cancer cells can be distinguished from their proliferating counterparts through image-based morphological analysis115. Senescence-associated morphological phenotypes (SAMPs) can be extracted from simple microscopy images and facilitate the exploration of both the heterogeneity between senescence contexts, and within an individual model, through the use of single target data and dimensionality reduction algorithms (e.g. tSNE/UMAP). These morphological profiles have recently been used to develop a feature-based classification tree for the identification of senescence in vitro and in vivo107. This work supports developments employing convolutional neural network deep learning methods, to generate computer vision-based tools of senescence classification116,117.Fig. 4 Senescence classification with machine learning.

With increasingly large and complex datasets, sophisticated machine learning algorithms represent a potential route to overcoming the challenges of senescence identification. These have been applied to develop classifiers based on a diverse range of data types including multimetric morphology imaging data, RNA-sequencing or sc-RNA-sequencing.

Collectively, these studies support a principle that dates to the earliest days of the senescence field, that senescent cells are morphologically fundamentally different from their proliferating counterparts118. Importantly, the ML methods employed in these studies were found to recapitulate in vivo, which has often not been the case for many canonical in vitro senescence hallmarks107,115. Application of sophisticated image analysis methodologies allows an increasingly complex assessment of morphological parameters, and the field of high throughput phenomics has potential to overhaul the requirements of senescent cell classification, particularly in contexts where the use of canonical markers is logistically restricted (e.g. screening) or biologically limited (Sen-Mark+ cancers and senescent cancer cells)114.

Machine learning has also been employed to provide insight to the increasingly complex datasets being generated by the senescence field. Jochems et al. developed the SENCAN classification model, which was constructed through bulk RNA sequencing data from 13 cancer cell lines induced to senescence via treatment with two small molecules112. SENCAN is an elastic net-based classifier, which identified 137 genes that collectively can be used to predict senescence, expanding the genes of interest beyond what might be considered “standard” senescence markers. Intriguingly, whilst SENCAN was trained with data from senescent cancer cells, it was able to correctly classify both senescent fibroblast and HUVEC cells, suggesting that a combination of ML and RNA-seq may be a route towards the so far elusive “universal” marker of senescence. However, the failure of SENCAN to classify non-malignant senescent aortic endothelial cells, emphasises that this remains a distant achievement for the field given the wide range of senescence contexts101.

The scale of this heterogeneity seems likely to continue expanding, especially due to the increased use of single-cell RNA sequencing, which allows insight within an individual senescence model. A notable example of this is the “SenMayo” classification tool, which (similar to SENCAN) employs the assessment of 125 genes to predict a senescence state119. Whilst this system was developed in the context of ageing, similar tools in the context of cancer could build on the groundwork of SENCAN to develop more robust predictors of senescence. Ultimately, as such tools require training on a wide range of data sets, endeavours such as the SenNet consortium and the construction of large atlases of senescent cell data will be invaluable to this120.

Future perspective

The overexpression p16 and p21 in a subset of cancers is a perplexing paradox, where in some situations the expression of a CDKi is counterintuitively linked to poor patient outcome. Furthermore, the high expression levels are often predictive of resistance to therapy. Interestingly, it appears that the localisation of these CDKi is important, with cytoplasmic expression of either p21 or p16 being associated with reduced overall survival. The localisation of these proteins raises interesting questions regarding alternative functionality and regulation they may have given the ability of the cancer cells to escape, or bypass, senescence induction. Pro-senescence therapies are an exciting area of ongoing research, aiming to specifically induce senescence in cancer cells, to allow the intrinsic tumour suppressor mechanism to take effect. This can also be coupled with senolytics, in a one-two punch strategy67. An alternative approach could involve the re-sensitisation of cancer cells to their endogenous overexpression of CDKi, p16 and/or p21. To fully elucidate the therapeutic potential of re-sensitisation of senescent-positive cancer cells, more research is required to understand the potential non-canonical role of CDKi in the context of different cellular localisation. Compounds facilitating localisation of CDKi to the nucleus could provide a previously unappreciated mechanism to induce pro-senescence in a cancer-specific manner.

The observation of that cancer cells have the potential to proliferate and drive tumour development while retaining key senescent proteins, such as p16, raises intriguing questions about the mechanisms underlying cancer progression. Additionally, the varied cellular localisation of p16 in different cancer types underscores the need to explore alternate roles and regulation mechanisms of p16 that may be exploited by cancer cells to evade senescence induction. Furthermore, the intricate interplay between p16 and other tumour suppressors, including p53 and p21, adds another layer of complexity to our understanding of cancer biology. The subcellular localization of p16 and p21, for instance, has been associated with differential prognostic implications in various cancer types. However, challenges with the identification of senescent cancer cells remains an outstanding issue, particularly in the context of “senescence marker positive cancer cells”. Overcoming these challenges will be essential to developing new targeted pro-senescence-based therapies. Overall, elucidating the molecular mechanisms underlying CDKi overexpression in cancer and their interactions with tumour suppressors holds promise for the development of therapeutic strategies and prognostic markers in cancer management. Continued research in this field is essential to unravel the full spectrum of p16 and p21 functions and thus the implications for cancer biology and therapy.

Acknowledgements

Emily O’Sullivan is funded by the Medical Research Council (MR/N014308/1), Ryan Wallis is funded by Barts Charity (MGU0537), and Federica Mossa is funded by the Biotechnology and Biological Sciences Research Council (BB/T008709/1). All figures were created with Biorender.com.

Author contributions

All authors contributed to concept of the manuscript, the drafting and writing of the manuscript and design of the figures. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Wang B Han J Elisseeff JH Demaria M The senescence-associated secretory phenotype and its physiological and pathological implications Nat. Rev. Mol. Cell Biol. 2024 10.1038/s41580-024-00727-x 39169166
Wang, B., Han, J., Elisseeff, J. H. & Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell Biol.10.1038/s41580-024-00727-x (2024).39169166 10.1038/s41580-024-00727-x
2. Evangelou K Belogiannis K Papaspyropoulos A Petty R Gorgoulis VG Escape from senescence: molecular basis and therapeutic ramifications J. Pathol. 2023 260 649 665 10.1002/path.6164 37550877
Evangelou, K., Belogiannis, K., Papaspyropoulos, A., Petty, R. & Gorgoulis, V. G. Escape from senescence: molecular basis and therapeutic ramifications. J. Pathol. 260, 649–665 (2023).37550877 10.1002/path.6164
3. Halazonetis TD Gorgoulis VG Bartek J An oncogene-induced DNA damage model for cancer development Science 2008 319 1352 1355 10.1126/science.1140735 18323444
Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355 (2008).18323444 10.1126/science.1140735
4. Serrano M Lin AW McCurrach ME Beach D Lowe SW Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 1997 88 593 602 10.1016/S0092-8674(00)81902-9 9054499
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).9054499 10.1016/S0092-8674(00)81902-9
5. Braig M Oncogene-induced senescence as an initial barrier in lymphoma development Nature 2005 436 660 665 10.1038/nature03841 16079837
Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–665 (2005).16079837 10.1038/nature03841
6. Michaloglou C BRAFE600-associated senescence-like cell cycle arrest of human naevi Nature 2005 436 720 724 10.1038/nature03890 16079850
Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005).16079850 10.1038/nature03890
7. Dhomen N Oncogenic Braf induces melanocyte senescence and melanoma in mice Cancer Cell 2009 15 294 303 10.1016/j.ccr.2009.02.022 19345328
Dhomen, N. et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294–303 (2009).19345328 10.1016/j.ccr.2009.02.022
8. Gray-Schopfer VC Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 2006 95 496 505 10.1038/sj.bjc.6603283 16880792
Gray-Schopfer, V. C. et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496–505 (2006).16880792 10.1038/sj.bjc.6603283
9. Lazzerini Denchi E Attwooll C Pasini D Helin K Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland Mol. Cell Biol. 2005 25 2660 2672 10.1128/MCB.25.7.2660-2672.2005 15767672
Lazzerini Denchi, E., Attwooll, C., Pasini, D. & Helin, K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol. Cell Biol. 25, 2660–2672 (2005).15767672 10.1128/MCB.25.7.2660-2672.2005
10. Collado M Tumour biology: senescence in premalignant tumours Nature 2005 436 642 10.1038/436642a 16079833
Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).16079833 10.1038/436642a
11. Dankort D A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors Genes Dev. 2007 21 379 384 10.1101/gad.1516407 17299132
Dankort, D. et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379–384 (2007).17299132 10.1101/gad.1516407
12. Chen Z Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis Nature 2005 436 725 730 10.1038/nature03918 16079851
Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).16079851 10.1038/nature03918
13. Jung SH mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53 Oncogene 2019 38 1639 1650 10.1038/s41388-018-0521-8 30337688
Jung, S. H. et al. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Oncogene 38, 1639–1650 (2019).30337688 10.1038/s41388-018-0521-8
14. Alimonti A A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis J. Clin. Invest. 2010 120 681 693 10.1172/JCI40535 20197621
Alimonti, A. et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 120, 681–693 (2010).20197621 10.1172/JCI40535
15. Young AP VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 Nat. Cell Biol. 2008 10 361 369 10.1038/ncb1699 18297059
Young, A. P. et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat. Cell Biol. 10, 361–369 (2008).18297059 10.1038/ncb1699
16. Collado M Serrano M Senescence in tumours: evidence from mice and humans Nat. Rev. Cancer 2010 10 51 57 10.1038/nrc2772 20029423
Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10, 51–57 (2010).20029423 10.1038/nrc2772
17. Sarkisian CJ Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis Nat. Cell Biol. 2007 9 493 505 10.1038/ncb1567 17450133
Sarkisian, C. J. et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9, 493–505 (2007).17450133 10.1038/ncb1567
18. Bartkova J Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints Nature 2006 444 633 637 10.1038/nature05268 17136093
Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).17136093 10.1038/nature05268
19. Abbadie C Pluquet O Pourtier A Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses? Cell Mol. Life Sci. 2017 74 4471 4509 10.1007/s00018-017-2587-9 28707011
Abbadie, C., Pluquet, O. & Pourtier, A. Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses? Cell Mol. Life Sci. 74, 4471–4509 (2017).28707011 10.1007/s00018-017-2587-9
20. Brenner AJ Stampfer MR Aldaz CM Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation Oncogene 1998 17 199 205 10.1038/sj.onc.1201919 9674704
Brenner, A. J., Stampfer, M. R. & Aldaz, C. M. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 17, 199–205 (1998).9674704 10.1038/sj.onc.1201919
21. Romanov SR Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes Nature 2001 409 633 637 10.1038/35054579 11214324
Romanov, S. R. et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633–637 (2001).11214324 10.1038/35054579
22. Buj R Leon KE Anguelov MA Aird KM Suppression of p16 alleviates the senescence-associated secretory phenotype Aging 2021 13 3290 3312 10.18632/aging.202640 33550279
Buj, R., Leon, K. E., Anguelov, M. A. & Aird, K. M. Suppression of p16 alleviates the senescence-associated secretory phenotype. Aging 13, 3290–3312 (2021).33550279 10.18632/aging.202640
23. Reyes J Fluctuations in p53 signaling allow escape from cell-cycle arrest Mol. Cell 2018 71 581 591.e585 10.1016/j.molcel.2018.06.031 30057196
Reyes, J. et al. Fluctuations in p53 signaling allow escape from cell-cycle arrest. Mol. Cell 71, 581–591.e585 (2018).30057196 10.1016/j.molcel.2018.06.031
24. Patel PL Suram A Mirani N Bischof O Herbig U Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence Proc. Natl Acad. Sci. USA 2016 113 E5024 E5033 10.1073/pnas.1602379113 27503890
Patel, P. L., Suram, A., Mirani, N., Bischof, O. & Herbig, U. Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence. Proc. Natl Acad. Sci. USA 113, E5024–E5033 (2016).27503890 10.1073/pnas.1602379113
25. Vogelstein B Lane D Levine AJ Surfing the p53 network Nature 2000 408 307 310 10.1038/35042675 11099028
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).11099028 10.1038/35042675
26. Ruas M Peters G The p16INK4a/CDKN2A tumor suppressor and its relatives Biochim. Biophys. Acta 1998 1378 F115 F177 9823374
Ruas, M. & Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378, F115–F177 (1998).9823374
27. Gil J Peters G Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all Nat. Rev. Mol. Cell Biol. 2006 7 667 677 10.1038/nrm1987 16921403
Gil, J. & Peters, G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7, 667–677 (2006).16921403 10.1038/nrm1987
28. Zuo L Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma Nat. Genet. 1996 12 97 99 10.1038/ng0196-97 8528263
Zuo, L. et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12, 97–99 (1996).8528263 10.1038/ng0196-97
29. Li J Poi MJ Tsai MD Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer Biochemistry 2011 50 5566 5582 10.1021/bi200642e 21619050
Li, J., Poi, M. J. & Tsai, M. D. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry 50, 5566–5582 (2011).21619050 10.1021/bi200642e
30. Nichols KE Malkin D Garber JE Fraumeni JF Li FP Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers Cancer Epidemiol. Biomark. Prev. 2001 10 83 87
Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F. & Li, F. P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomark. Prev. 10, 83–87 (2001).
31. Ruhland MK Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis Nat. Commun. 2016 7 11762 10.1038/ncomms11762 27272654
Ruhland, M. K. et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 7, 11762 (2016).27272654 10.1038/ncomms11762
32. Prieto LI Senescent alveolar macrophages promote early-stage lung tumorigenesis Cancer Cell 2023 41 1261 1275.e1266 10.1016/j.ccell.2023.05.006 37267954
Prieto, L. I. et al. Senescent alveolar macrophages promote early-stage lung tumorigenesis. Cancer Cell 41, 1261–1275.e1266 (2023).37267954 10.1016/j.ccell.2023.05.006
33. Haston S Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer Cancer Cell 2023 41 1242 1260.e1246 10.1016/j.ccell.2023.05.004 37267953
Haston, S. et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell 41, 1242–1260.e1246 (2023).37267953 10.1016/j.ccell.2023.05.004
34. Krishnamurthy J Ink4a/Arf expression is a biomarker of aging J. Clin. Invest. 2004 114 1299 1307 10.1172/JCI22475 15520862
Krishnamurthy, J. et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114, 1299–1307 (2004).15520862 10.1172/JCI22475
35. Münger K Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product EMBO J. 1989 8 4099 4105 10.1002/j.1460-2075.1989.tb08594.x 2556261
Münger, K. et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099–4105 (1989).2556261 10.1002/j.1460-2075.1989.tb08594.x
36. da Mata S P16 and HPV genotype significance in HPV-associated cervical cancer-a large cohort of two tertiary referral centers Int. J. Mol. Sci. 2021 22 2294 10.3390/ijms22052294 33669021
da Mata, S. et al. P16 and HPV genotype significance in HPV-associated cervical cancer-a large cohort of two tertiary referral centers. Int. J. Mol. Sci. 22, 2294 (2021).33669021 10.3390/ijms22052294
37. Chinnam M Goodrich DW RB1, development, and cancer Curr. Top. Dev. Biol. 2011 94 129 169 10.1016/B978-0-12-380916-2.00005-X 21295686
Chinnam, M. & Goodrich, D. W. RB1, development, and cancer. Curr. Top. Dev. Biol. 94, 129–169 (2011).21295686 10.1016/B978-0-12-380916-2.00005-X
38. Sen M p16 controls epithelial cell growth and suppresses carcinogenesis through mechanisms that do not require RB1 function Oncogenesis 2017 6 e320 10.1038/oncsis.2017.5 28414317
Sen, M. et al. p16 controls epithelial cell growth and suppresses carcinogenesis through mechanisms that do not require RB1 function. Oncogenesis 6, e320 (2017).28414317 10.1038/oncsis.2017.5
39. Geradts J Kratzke RA Niehans GA Lincoln CE Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression Cancer Res. 1995 55 6006 6011 8521382
Geradts, J., Kratzke, R. A., Niehans, G. A. & Lincoln, C. E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 55, 6006–6011 (1995).8521382
40. Haller F Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis Histopathology 2010 56 305 318 10.1111/j.1365-2559.2010.03478.x 20459531
Haller, F. et al. Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis. Histopathology 56, 305–318 (2010).20459531 10.1111/j.1365-2559.2010.03478.x
41. Armes JE Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein Int. J. Gynecol. Pathol. 2005 24 363 368 10.1097/01.pgp.0000172083.94934.1e 16175083
Armes, J. E. et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int. J. Gynecol. Pathol. 24, 363–368 (2005).16175083 10.1097/01.pgp.0000172083.94934.1e
42. Todd MC Sclafani RA Langan TA Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein Oncogene 2000 19 258 264 10.1038/sj.onc.1203289 10645004
Todd, M. C., Sclafani, R. A. & Langan, T. A. Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein. Oncogene 19, 258–264 (2000).10645004 10.1038/sj.onc.1203289
43. Zhao P Mao X Talbot IC Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence World J. Gastroenterol. 2006 12 6391 6396 10.3748/wjg.v12.i39.6391 17072968
Zhao, P., Mao, X. & Talbot, I. C. Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J. Gastroenterol. 12, 6391–6396 (2006).17072968 10.3748/wjg.v12.i39.6391
44. Lam AK Ong K Giv MJ Ho YH p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types Pathology 2008 40 580 585 10.1080/00313020802320713 18752124
Lam, A. K., Ong, K., Giv, M. J. & Ho, Y. H. p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 40, 580–585 (2008).18752124 10.1080/00313020802320713
45. Nilsson K Svensson S Landberg G Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior Mod. Pathol. 2004 17 1464 1474 10.1038/modpathol.3800220 15257310
Nilsson, K., Svensson, S. & Landberg, G. Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. Mod. Pathol. 17, 1464–1474 (2004).15257310 10.1038/modpathol.3800220
46. Angiero F Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity Anticancer Res. 2008 28 2535 2539 19035275
Angiero, F. et al. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res. 28, 2535–2539 (2008).19035275
47. Milde-Langosch K Bamberger AM Rieck G Kelp B Löning T Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype Breast Cancer Res. Treat. 2001 67 61 70 10.1023/A:1010623308275 11518467
Milde-Langosch, K., Bamberger, A. M., Rieck, G., Kelp, B. & Löning, T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res. Treat. 67, 61–70 (2001).11518467 10.1023/A:1010623308275
48. Emig R Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation Br. J. Cancer 1998 78 1661 1668 10.1038/bjc.1998.739 9862580
Emig, R. et al. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br. J. Cancer 78, 1661–1668 (1998).9862580 10.1038/bjc.1998.739
49. Abou-Bakr AA Eldweny HI p16 expression correlates with basal-like triple-negative breast carcinoma Ecancermedicalscience 2013 7 317 23717338
Abou-Bakr, A. A. & Eldweny, H. I. p16 expression correlates with basal-like triple-negative breast carcinoma. Ecancermedicalscience 7, 317 (2013).23717338
50. Bohn OL Fuertes-Camilo M Navarro L Saldivar J Sanchez-Sosa S p16INK4a expression in basal-like breast carcinoma Int. J. Clin. Exp. Pathol. 2010 3 600 607 20661408
Bohn, O. L., Fuertes-Camilo, M., Navarro, L., Saldivar, J. & Sanchez-Sosa, S. p16INK4a expression in basal-like breast carcinoma. Int. J. Clin. Exp. Pathol. 3, 600–607 (2010).20661408
51. Shen WW Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma Neoplasia 2007 9 812 819 10.1593/neo.07403 17971901
Shen, W. W. et al. Expression of anion exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic adenocarcinoma. Neoplasia 9, 812–819 (2007).17971901 10.1593/neo.07403
52. Jung YS Qian Y Chen X Examination of the expanding pathways for the regulation of p21 expression and activity Cell Signal 2010 22 1003 1012 10.1016/j.cellsig.2010.01.013 20100570
Jung, Y. S., Qian, Y. & Chen, X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 22, 1003–1012 (2010).20100570 10.1016/j.cellsig.2010.01.013
53. Huang Y The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients J. Gastroenterol. 2014 49 1441 1452 10.1007/s00535-013-0900-4 24127074
Huang, Y. et al. The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients. J. Gastroenterol. 49, 1441–1452 (2014).24127074 10.1007/s00535-013-0900-4
54. Xia W Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients Clin. Cancer Res. 2004 10 3815 3824 10.1158/1078-0432.CCR-03-0527 15173090
Xia, W. et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 10, 3815–3824 (2004).15173090 10.1158/1078-0432.CCR-03-0527
55. Galanos P Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing Nat. Cell Biol. 2016 18 777 789 10.1038/ncb3378 27323328
Galanos, P. et al. Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nat. Cell Biol. 18, 777–789 (2016).27323328 10.1038/ncb3378
56. Galanos P Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability Genome Biol. 2018 19 37 10.1186/s13059-018-1401-9 29548335
Galanos, P. et al. Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability. Genome Biol. 19, 37 (2018).29548335 10.1186/s13059-018-1401-9
57. André F Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer N. Engl. J. Med. 2019 380 1929 1940 10.1056/NEJMoa1813904 31091374
André, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019).31091374 10.1056/NEJMoa1813904
58. Yip HYK Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer NPJ Precis. Oncol. 2024 8 20 10.1038/s41698-024-00496-y 38273040
Yip, H. Y. K. et al. Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. NPJ Precis. Oncol. 8, 20 (2024).38273040 10.1038/s41698-024-00496-y
59. Galanos P Author Correction: Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability Genome Biol. 2022 23 107 10.1186/s13059-022-02678-y 35484586
Galanos, P. et al. Author Correction: Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability. Genome Biol. 23, 107 (2022).35484586 10.1186/s13059-022-02678-y
60. Schmitt CA Wang B Demaria M Senescence and cancer - role and therapeutic opportunities Nat. Rev. Clin. Oncol. 2022 19 619 636 10.1038/s41571-022-00668-4 36045302
Schmitt, C. A., Wang, B. & Demaria, M. Senescence and cancer - role and therapeutic opportunities. Nat. Rev. Clin. Oncol. 19, 619–636 (2022).36045302 10.1038/s41571-022-00668-4
61. Shahbandi A Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80 Nat. Cancer 2022 3 1513 1533 10.1038/s43018-022-00466-y 36482233
Shahbandi, A. et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat. Cancer 3, 1513–1533 (2022).36482233 10.1038/s43018-022-00466-y
62. Chaib S The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2 Nat. Cancer 2024 5 448 462 10.1038/s43018-023-00712-x 38267628
Chaib, S. et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat. Cancer 5, 448–462 (2024).38267628 10.1038/s43018-023-00712-x
63. Puig PE Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy Cell Biol. Int. 2008 32 1031 1043 10.1016/j.cellbi.2008.04.021 18550395
Puig, P. E. et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol. Int. 32, 1031–1043 (2008).18550395 10.1016/j.cellbi.2008.04.021
64. Wang Q Polyploidy road to therapy-induced cellular senescence and escape Int. J. Cancer 2013 132 1505 1515 10.1002/ijc.27810 22945332
Wang, Q. et al. Polyploidy road to therapy-induced cellular senescence and escape. Int. J. Cancer 132, 1505–1515 (2013).22945332 10.1002/ijc.27810
65. Mosieniak G Polyploidy formation in doxorubicin-treated cancer cells can favor escape from senescence Neoplasia 2015 17 882 893 10.1016/j.neo.2015.11.008 26696370
Mosieniak, G. et al. Polyploidy formation in doxorubicin-treated cancer cells can favor escape from senescence. Neoplasia 17, 882–893 (2015).26696370 10.1016/j.neo.2015.11.008
66. Rohnalter V A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype Oncotarget 2015 6 40005 40025 10.18632/oncotarget.5552 26503466
Rohnalter, V. et al. A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget 6, 40005–40025 (2015).26503466 10.18632/oncotarget.5552
67. Wang L Lankhorst L Bernards R Exploiting senescence for the treatment of cancer Nat. Rev. Cancer 2022 22 340 355 10.1038/s41568-022-00450-9 35241831
Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340–355 (2022).35241831 10.1038/s41568-022-00450-9
68. Sieben CJ Sturmlechner I van de Sluis B van Deursen JM Two-step senescence-focused cancer therapies Trends Cell Biol. 2018 28 723 737 10.1016/j.tcb.2018.04.006 29776716
Sieben, C. J., Sturmlechner, I., van de Sluis, B. & van Deursen, J. M. Two-step senescence-focused cancer therapies. Trends Cell Biol. 28, 723–737 (2018).29776716 10.1016/j.tcb.2018.04.006
69. Nardella C Clohessy JG Alimonti A Pandolfi PP Pro-senescence therapy for cancer treatment Nat. Rev. Cancer 2011 11 503 511 10.1038/nrc3057 21701512
Nardella, C., Clohessy, J. G., Alimonti, A. & Pandolfi, P. P. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 11, 503–511 (2011).21701512 10.1038/nrc3057
70. Vassilev LT In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004 303 844 848 10.1126/science.1092472 14704432
Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).14704432 10.1126/science.1092472
71. Bykov VJ Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat. Med. 2002 8 282 288 10.1038/nm0302-282 11875500
Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282–288 (2002).11875500 10.1038/nm0302-282
72. Fry DW Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol. Cancer Ther. 2004 3 1427 10.1158/1535-7163.1427.3.11 15542782
Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427 (2004).15542782 10.1158/1535-7163.1427.3.11
73. Finn RS Palbociclib and letrozole in advanced breast cancer N. Engl. J. Med. 2016 375 1925 1936 10.1056/NEJMoa1607303 27959613
Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925–1936 (2016).27959613 10.1056/NEJMoa1607303
74. Klein ME Kovatcheva M Davis LE Tap WD Koff A CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought Cancer Cell 2018 34 9 20 10.1016/j.ccell.2018.03.023 29731395
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D. & Koff, A. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell 34, 9–20 (2018).29731395 10.1016/j.ccell.2018.03.023
75. O’Leary B The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial Cancer Discov. 2018 8 1390 1403 10.1158/2159-8290.CD-18-0264 30206110
O’Leary, B. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 8, 1390–1403 (2018).30206110 10.1158/2159-8290.CD-18-0264
76. Yang C Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence Oncogene 2017 36 2255 2264 10.1038/onc.2016.379 27748766
Yang, C. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene 36, 2255–2264 (2017).27748766 10.1038/onc.2016.379
77. Palafox M High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER Nat. Commun. 2022 13 5258 10.1038/s41467-022-32828-6 36071033
Palafox, M. et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER. Nat. Commun. 13, 5258 (2022).36071033 10.1038/s41467-022-32828-6
78. Guan X Stromal senescence by prolonged CDK4/6 inhibition potentiates tumor growth Mol. Cancer Res. 2017 15 237 249 10.1158/1541-7786.MCR-16-0319 28039358
Guan, X. et al. Stromal senescence by prolonged CDK4/6 inhibition potentiates tumor growth. Mol. Cancer Res. 15, 237–249 (2017).28039358 10.1158/1541-7786.MCR-16-0319
79. Kirkland JL Tchkonia T Zhu Y Niedernhofer LJ Robbins PD The clinical potential of senolytic drugs J. Am. Geriatr. Soc. 2017 65 2297 2301 10.1111/jgs.14969 28869295
Kirkland, J. L., Tchkonia, T., Zhu, Y., Niedernhofer, L. J. & Robbins, P. D. The clinical potential of senolytic drugs. J. Am. Geriatr. Soc. 65, 2297–2301 (2017).28869295 10.1111/jgs.14969
80. Zhu Y New agents that target senescent cells: the flavone, fisetin, and the BCL-X Aging 2017 9 955 963 10.18632/aging.101202 28273655
Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-X. Aging 9, 955–963 (2017).28273655 10.18632/aging.101202
81. Baker DJ Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan Nature 2016 530 184 189 10.1038/nature16932 26840489
Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016).26840489 10.1038/nature16932
82. Zhu Y The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs Aging Cell 2015 14 644 658 10.1111/acel.12344 25754370
Zhu, Y. et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658 (2015).25754370 10.1111/acel.12344
83. Xu M Senolytics improve physical function and increase lifespan in old age Nat. Med. 2018 24 1246 1256 10.1038/s41591-018-0092-9 29988130
Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. Nat. Med. 24, 1246–1256 (2018).29988130 10.1038/s41591-018-0092-9
84. Guerrero A Cardiac glycosides are broad-spectrum senolytics Nat. Metab. 2019 1 1074 1088 10.1038/s42255-019-0122-z 31799499
Guerrero, A. et al. Cardiac glycosides are broad-spectrum senolytics. Nat. Metab. 1, 1074–1088 (2019).31799499 10.1038/s42255-019-0122-z
85. Triana-Martínez F Identification and characterization of Cardiac Glycosides as senolytic compounds Nat. Commun. 2019 10 4731 10.1038/s41467-019-12888-x 31636264
Triana-Martínez, F. et al. Identification and characterization of Cardiac Glycosides as senolytic compounds. Nat. Commun. 10, 4731 (2019).31636264 10.1038/s41467-019-12888-x
86. Zhu Y Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors Aging Cell 2016 15 428 435 10.1111/acel.12445 26711051
Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2016).26711051 10.1111/acel.12445
87. Wang L High-throughput functional genetic and compound screens identify targets for senescence induction in cancer Cell Rep. 2017 21 773 783 10.1016/j.celrep.2017.09.085 29045843
Wang, L. et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer. Cell Rep. 21, 773–783 (2017).29045843 10.1016/j.celrep.2017.09.085
88. Wang C Inducing and exploiting vulnerabilities for the treatment of liver cancer Nature 2019 574 268 272 10.1038/s41586-019-1607-3 31578521
Wang, C. et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268–272 (2019).31578521 10.1038/s41586-019-1607-3
89. Demaria M An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA Dev. Cell 2014 31 722 733 10.1016/j.devcel.2014.11.012 25499914
Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722–733 (2014).25499914 10.1016/j.devcel.2014.11.012
90. Xue W Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 2007 445 656 660 10.1038/nature05529 17251933
Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).17251933 10.1038/nature05529
91. Kang TW Senescence surveillance of pre-malignant hepatocytes limits liver cancer development Nature 2011 479 547 551 10.1038/nature10599 22080947
Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547–551 (2011).22080947 10.1038/nature10599
92. Ruscetti M NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination Science 2018 362 1416 1422 10.1126/science.aas9090 30573629
Ruscetti, M. et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362, 1416–1422 (2018).30573629 10.1126/science.aas9090
93. Marin I Cellular senescence is immunogenic and promotes antitumor immunity Cancer Discov. 2023 13 410 431 10.1158/2159-8290.CD-22-0523 36302218
Marin, I. et al. Cellular senescence is immunogenic and promotes antitumor immunity. Cancer Discov. 13, 410–431 (2023).36302218 10.1158/2159-8290.CD-22-0523
94. Chen HA Senescence rewires microenvironment sensing to facilitate antitumor immunity Cancer Discov. 2023 13 432 453 10.1158/2159-8290.CD-22-0528 36302222
Chen, H. A. et al. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 13, 432–453 (2023).36302222 10.1158/2159-8290.CD-22-0528
95. Gorgoulis V Cellular senescence: defining a path forward Cell 2019 179 813 827 10.1016/j.cell.2019.10.005 31675495
Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179, 813–827 (2019).31675495 10.1016/j.cell.2019.10.005
96. Hanahan D Hallmarks of cancer: new dimensions Cancer Discov. 2022 12 31 46 10.1158/2159-8290.CD-21-1059 35022204
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).35022204 10.1158/2159-8290.CD-21-1059
97. Chavez KJ Garimella SV Lipkowitz S Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer Breast Dis. 2010 32 35 48 10.3233/BD-2010-0307 21778573
Chavez, K. J., Garimella, S. V. & Lipkowitz, S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32, 35–48 (2010).21778573 10.3233/BD-2010-0307
98. Romagosa C p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors Oncogene 2011 30 2087 2097 10.1038/onc.2010.614 21297668
Romagosa, C. et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 30, 2087–2097 (2011).21297668 10.1038/onc.2010.614
99. Hayflick L Moorhead PS The serial cultivation of human diploid cell strains Exp. Cell Res. 1961 25 585 621 10.1016/0014-4827(61)90192-6 13905658
Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).13905658 10.1016/0014-4827(61)90192-6
100. Colville A Death-seq identifies regulators of cell death and senolytic therapies Cell Metab 2022 35 1814 1829 10.1016/j.cmet.2023.08.008
Colville, A. et al. Death-seq identifies regulators of cell death and senolytic therapies. Cell Metab. 35, 1814–1829 (2022).10.1016/j.cmet.2023.08.008
101. Kohli J Algorithmic assessment of cellular senescence in experimental and clinical specimens Nat. Protoc. 2021 16 2471 2498 10.1038/s41596-021-00505-5 33911261
Kohli, J. et al. Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat. Protoc. 16, 2471–2498 (2021).33911261 10.1038/s41596-021-00505-5
102. Wallis R Bishop CL Death-seq and ye shall find: a novel screening strategy for dying cells Cell Metab. 2023 35 1675 1676 10.1016/j.cmet.2023.09.003 37793342
Wallis, R. & Bishop, C. L. Death-seq and ye shall find: a novel screening strategy for dying cells. Cell Metab. 35, 1675–1676 (2023).37793342 10.1016/j.cmet.2023.09.003
103. Nowakowski RS Lewin SB Miller MW Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population J. Neurocytol. 1989 18 311 318 10.1007/BF01190834 2746304
Nowakowski, R. S., Lewin, S. B. & Miller, M. W. Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population. J. Neurocytol. 18, 311–318 (1989).2746304 10.1007/BF01190834
104. Dimri GP A biomarker that identifies senescent human cells in culture and in aging skin in vivo Proc. Natl Acad. Sci. USA 1995 92 9363 9367 10.1073/pnas.92.20.9363 7568133
Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).7568133 10.1073/pnas.92.20.9363
105. Yang NC Hu ML The limitations and validities of senescence associated-beta-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells Exp. Gerontol. 2005 40 813 819 10.1016/j.exger.2005.07.011 16154306
Yang, N. C. & Hu, M. L. The limitations and validities of senescence associated-beta-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells. Exp. Gerontol. 40, 813–819 (2005).16154306 10.1016/j.exger.2005.07.011
106. Hwang ES Yoon G Kang HT A comparative analysis of the cell biology of senescence and aging Cell Mol. Life Sci. 2009 66 2503 2524 10.1007/s00018-009-0034-2 19421842
Hwang, E. S., Yoon, G. & Kang, H. T. A comparative analysis of the cell biology of senescence and aging. Cell Mol. Life Sci. 66, 2503–2524 (2009).19421842 10.1007/s00018-009-0034-2
107. Duran I Detection of senescence using machine learning algorithms based on nuclear features Nat. Commun. 2024 15 1041 10.1038/s41467-024-45421-w 38310113
Duran, I. et al. Detection of senescence using machine learning algorithms based on nuclear features. Nat. Commun. 15, 1041 (2024).38310113 10.1038/s41467-024-45421-w
108. d’Adda di Fagagna F A DNA damage checkpoint response in telomere-initiated senescence Nature 2003 426 194 198 10.1038/nature02118 14608368
d’Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198 (2003).14608368 10.1038/nature02118
109. Di Micco R Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer Nat. Cell Biol. 2011 13 292 302 10.1038/ncb2170 21336312
Di Micco, R. et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat. Cell Biol. 13, 292–302 (2011).21336312 10.1038/ncb2170
110. Coppé JP Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor PLoS Biol. 2008 6 2853 2868 10.1371/journal.pbio.0060301 19053174
Coppé, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).19053174 10.1371/journal.pbio.0060301
111. Hoare M NOTCH1 mediates a switch between two distinct secretomes during senescence Nat. Cell Biol. 2016 18 979 992 10.1038/ncb3397 27525720
Hoare, M. et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat. Cell Biol. 18, 979–992 (2016).27525720 10.1038/ncb3397
112. Jochems F The cancer SENESCopedia: a delineation of cancer cell senescence Cell Rep. 2021 36 109441 10.1016/j.celrep.2021.109441 34320349
Jochems, F. et al. The cancer SENESCopedia: a delineation of cancer cell senescence. Cell Rep. 36, 109441 (2021).34320349 10.1016/j.celrep.2021.109441
113. Coppé JP Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype J. Biol. Chem. 2011 286 36396 36403 10.1074/jbc.M111.257071 21880712
Coppé, J. P. et al. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J. Biol. Chem. 286, 36396–36403 (2011).21880712 10.1074/jbc.M111.257071
114. Hughes BK Wallis R Bishop CL Yearning for machine learning: applications for the classification and characterisation of senescence Cell Tissue Res. 2023 394 1 16 10.1007/s00441-023-03768-4 37016180
Hughes, B. K., Wallis, R. & Bishop, C. L. Yearning for machine learning: applications for the classification and characterisation of senescence. Cell Tissue Res. 394, 1–16 (2023).37016180 10.1007/s00441-023-03768-4
115. Wallis R Senescence-associated morphological profiles (SAMPs): an image-based phenotypic profiling method for evaluating the inter and intra model heterogeneity of senescence Aging 2022 14 4220 4246 10.18632/aging.204072 35580013
Wallis, R. et al. Senescence-associated morphological profiles (SAMPs): an image-based phenotypic profiling method for evaluating the inter and intra model heterogeneity of senescence. Aging 14, 4220–4246 (2022).35580013 10.18632/aging.204072
116. Heckenbach I Nuclear morphology is a deep learning biomarker of cellular senescence Nat. Aging 2022 2 742 755 10.1038/s43587-022-00263-3 37118134
Heckenbach, I. et al. Nuclear morphology is a deep learning biomarker of cellular senescence. Nat. Aging 2, 742–755 (2022).37118134 10.1038/s43587-022-00263-3
117. Kusumoto D Anti-senescent drug screening by deep learning-based morphology senescence scoring Nat. Commun. 2021 12 257 10.1038/s41467-020-20213-0 33431893
Kusumoto, D. et al. Anti-senescent drug screening by deep learning-based morphology senescence scoring. Nat. Commun. 12, 257 (2021).33431893 10.1038/s41467-020-20213-0
118. Greenberg SB Grove GL Cristofalo VJ Cell size in aging monolayer cultures In Vitro 1977 13 297 300 10.1007/BF02616174 326658
Greenberg, S. B., Grove, G. L. & Cristofalo, V. J. Cell size in aging monolayer cultures. In Vitro 13, 297–300 (1977).326658 10.1007/BF02616174
119. Saul D A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues Nat. Commun. 2022 13 4827 10.1038/s41467-022-32552-1 35974106
Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).35974106 10.1038/s41467-022-32552-1
120. Consortium S NIH SenNet consortium to map senescent cells throughout the human lifespan to understand physiological health Nat. Aging 2022 2 1090 1100 10.1038/s43587-022-00326-5 36936385
Consortium, S. NIH SenNet consortium to map senescent cells throughout the human lifespan to understand physiological health. Nat. Aging 2, 1090–1100 (2022).36936385 10.1038/s43587-022-00326-5
